On-Q-ity Sees CTC Test Value for Pharma Studies, PGx Efforts | GenomeWeb

By Edward Winnick

SAN FRANCISCO (GenomeWeb News) – With initial efforts aimed at bringing its circulating tumor cell platform to drug development researchers, On-Q-ity also has its sights set on the clinic, pharmacogenomics market, and detection of additional kinds of cells.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.